Announcements Trials
Browse Landscape

Phase

Phase 2 12Phase 1 6Phase 1/2 5Phase NA 1Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Lymphoma 18Lymphoma, Large B-Cell, Diffuse 12Lymphoma, Non-Hodgkin 9Lymphoma, B-Cell, Marginal Zone 4Leukemia 4Lymphoma, Mantle-Cell 3Lymphoma, Follicular 3Hodgkin Disease 3Waldenstrom Macroglobulinemia 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Nausea 2Leukemia, Lymphocytic, Chronic, B-Cell 2Vomiting 1Orbital lymphoma 1Myelodysplastic Syndromes 1Myasthenia Gravis 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large-Cell, Anaplastic 1Immunoblastic Lymphadenopathy 1Central Nervous System Neoplasms 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 15Antilymphocyte Serum 11fludarabine phosphate 10Cyclosporine 9Busulfan 9Peripheral Blood Stem Cell Transplantation 8Mycophenolic Acid 7Filgrastim 7Methotrexate 6Whole-Body Irradiation 5Melphalan 5fludarabine 4Radiotherapy 4Methylprednisolone 4Cord Blood Stem Cell Transplantation 4Tacrolimus 3Psychiatric Rehabilitation 3Palliative Care 3Blood Specimen Collection 3sargramostim 2Thiotepa 2Therapeutics 2Stem Cell Transplantation 2Polymerase Chain Reaction 2Injections 2Granulocyte Colony-Stimulating Factor 2Dexamethasone 2Cytarabine 2Behavior Therapy 2Ascorbic Acid 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Myelodysplastic Syndromes × Rituximab × Clear all
NCT00648037 2016-02-01

Rituximab (Rituxan) for the Prevention of EBV-LPD Epstein Barr Virus (EBV) Lymphoproliferative Disorder Post T Cell Depleted Unrelated and HLA Mis-matched Related HSCT

Memorial Sloan Kettering Cancer Center

Phase NA Completed
26 enrolled 6 charts
LymphoidMyeloidOther hematologic neoplasm

Hodgkin Disease, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡